RECRUITING Not applicable ClinicalTrials.gov

Histotripsy x Pancreatic Cancer

Sponsor: The University of Hong Kong • ClinicalTrials.gov ID: NCT07873606

Registry updated: 2026-10-14

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies, with 5-year survival around 12% despite advances in surgery, chemotherapy, and radiotherapy. Existing ablative therapies (RFA, microwave, irreversible electroporation) are limited by thermal injury risk, proximity to vessels/ducts. Novel local therapies that can be integrated with systemic regimens are urgently needed. Histotripsy is a non-thermal focused ultrasound modality that uses controlled cavitation to mechanically liquefy tissue without thermal coagulation or ionizing radiation, with precision under real-time ultrasound guidance. Preclinical and early translational work in pancreatic models shows that histotripsy can safely ablate pancreatic tissue while sparing major vessels and ducts in large-animal models, and can alter the tumour microenvironment (TME) with increased release of damage-associated molecular patterns (DAMPs), enhanced dendritic cell and macrophage activation, and increased CD8+ T-cell infiltration in murine pancreatic tumours. This proposal aims to evaluate the safety, local tumour control, and immunologic effects of histotripsy in pancreatic cancer especially PDAC, positioning it as a platform to enhance responsiveness to contemporary systemic therapies. The HistoSonics Histotripsy System is now registered in the Medical Device Administration Control System from Department of Health in Hong Kong (HKMD no: 252842).

Interventions

Histotripsy (Radiation)
Histotripsy is a promising non-invasive technique that uses high-intensity ultrasound waves to disrupt tissue without damaging surrounding structures. It works by using high-intensity ultrasound waves to create microscopic bubbles within the tumour tissue. These bubbles rapidly expand and collapse, generating shock waves that disrupt the tissue. The technique is highly precise and can be targeted to specific areas of the liver, allowing for selective destruction of tumour cells while minimizing damage to healthy tissue. Other Name:

Eligibility criteria

Inclusion Criteria: * Age ≥ 18 years old * Fit for general anaesthesia * Unresectable pancreatic cancer with, or without vascular encasement * With or without distant metastasis * Without portal vein thrombosis * Good performance status: 1. Tumour visible and targetable by ultrasound with acceptable acoustic windows 2. Adequate hematologic, hepatic, and renal function Exclusion Criteria: * Refusal to take part in clinical trial * Portal vein thrombosis present * Not fit for general anaesthesia * Poor general condition with limited life expectancy * Uncontrolled coagulopathy * Extensive bowel interposition preventing safe targeting, per recent porcine safety data linking mis-targeting to bowel injury

Conditions

Pancreatic Tumours

Locations

The University of Hong Kong — Hong Kong, Hong Kong

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment